Drugs and patents in ATC class H04A - GLYCOGENOLYTIC HORMONES

Last updated: June 3, 2026

Market dynamics and patent landscape for ATC Class H04A (glycogenolytic hormones): What patents protect diabetes and obesity-adjacent glucagon therapies, how exclusivity timelines play out, and where generics and biosimilars face risk?

Executive summary

ATC H04A (glycogenolytic hormones) is dominated by glucagon-based incretin and counter-regulatory glucose therapies rather than classic oncology biologics. The patent and exclusivity landscape is largely a patchwork of (1) molecule/biologic composition protections, (2) delivery-device and formulation patents for intranasal, prefilled auto-injector, and stable aqueous solutions, and (3) secondary method-of-use protections tied to emergency hypoglycemia management and rescue dosing. Market dynamics hinge on insurer coverage for emergency glucagon products, conversion of device-native formulations, and substitution friction created by autoinjector/intranasal usability. Generic entry is most constrained where Orange Book-registered formulation and device patents remain unexpired, or where method-of-use and manufacturing process patents survive. The highest near-term patent pressure concentrates in single-ingredient glucagon products as device line extensions roll into their own patent estates.

What products define ATC H04A (glycogenolytic hormones) and where is market demand concentrated?

Featured snippet answer: ATC H04A demand concentrates in emergency treatment of severe hypoglycemia (glucagon rescue) and related counter-regulatory glucose rescue settings, with competitive differentiation driven by formulation stability and delivery system usability (auto-injectors, prefilled syringes, and intranasal devices).

Key commercial segments

Severe hypoglycemia rescue in diabetes care
- Setting: home, school, workplace, and caregiver use.
- Drivers: speed of administration, ease of use, needle avoidance, and stability at ambient temperatures.
Hospital and EMS stock
- Drivers: inventory stability, shelf life, device reliability, and clinician familiarity.
Payer coverage and formulary inclusion
- Drivers: per-dose reimbursement, patient-assistance programs, contract pharmacy dynamics, and step edits for non-preferred devices.

Competitive archetypes inside H04A

Ready-to-use injectable glucagon (including prefilled formats)
Intranasal glucagon rescue (device-led)
Adjunct glucagon analogs where approved indications align with emergency hypoglycemia rescue (and where device and formulation patents create additional barriers)

What patents protect glucagon-based H04A therapies (composition, formulation, and method-of-use)?

Featured snippet answer: Patent protection for H04A products typically spans biologic/active ingredient IP, formulation stability (including aqueous concentration, pH, excipient systems), device integration (auto-injector and intranasal delivery), and method-of-use claims tied to emergency hypoglycemia dosing and administration steps.

How patent estates are structured for glucagon rescue products

1) Composition and biologic substance claims

Claims covering glucagon or glucagon variants, sequences, and binding/functional equivalents.
Scope often narrows around the exact claimed sequence and physicochemical definitions.

2) Formulation and stability claims

Targets:
- stable glucagon in ready-to-use aqueous systems
- control of aggregation, deamidation, and precipitation
- excipient systems (buffers, tonicity agents, surfactants/complexing agents)
- presentation-specific concentration ranges and fill-volume constraints

3) Device and delivery system claims

Auto-injectors and inhalation/nasal delivery are common patent hotspots.
Claims cover:
- spring-driven mechanism timing
- needle geometry and safety features
- internal venting/priming steps
- nasal applicator geometry and dose metering

4) Method-of-use claims

Commonly claim:
- administration in severe hypoglycemia
- caregiver-directed dosing protocols
- rescue algorithms (treatment after certain glucose thresholds or symptom onset criteria)

Where generic substitution is actually blocked

Generic entry typically fails on one of three axes:

device patents prevent a “design-around” intranasal or auto-injector form factor
formulation patents prevent stability-equivalent aqueous presentation
method-of-use patents force label carve-outs or create Paragraph IV leverage that delays FDA approval for the protected use

How many patents cover major glucagon rescue products in ATC H04A, and what assignees dominate?

Featured snippet answer: Coverage is often concentrated in a small number of assignees controlling the leading glucagon rescue brands and their delivery systems. Estates frequently include layered continuation filings extending into secondary patent years for formulations, devices, and manufacturing methods.

Patent estate patterns (what to look for in the USPTO and Orange Book)

Look for “listed” Orange Book patents tied to the NDA’s active and drug product.
For biologics not always listed in Orange Book, track:
- formulation/manufacturing patents in USPTO publication families
- device patents in separate application families
- method-of-use patents in continuation-heavy family trees

Assignee concentration risk

Estates skew toward:
- originator glucagon portfolio holders
- device-integrated partners (mechanical delivery and nasal metering)
- formulation science groups in major pharma

When does exclusivity for H04A glucagon therapies expire, and what are the key milestone gates?

Featured snippet answer: Exclusivity timelines depend on whether the product is governed by biologics exclusivity, Orange Book patent listings with statutory patent term, and any pediatric exclusivity add-ons. Practically, the “last gate” is the last Orange Book patent to expire or the outcome of patent litigation around listed patents.

Practical exclusivity gating logic

Data exclusivity
- Blocks FDA approval for certain periods for new applications, often regardless of patent status.
Orange Book patent expiration
- Drives whether ANDA entry can launch immediately post-expiration.
Biologics exclusivity (if applicable)
- Affects the timing of biosimilar/15-month-type pathways.
Litigation and settlement
- Automatic stays and negotiated launch dates reshape actual entry timing.

Featured snippet: timeline outcome hierarchy

If listed patents expire later than exclusivity, patents control.
If litigation stays extend beyond patent expiration, settlement controls.
If device and formulation patents survive even after composition patents expire, launch is delayed or changes label/device.

What patent expiration dates matter most for biosimilar and generic entry risk in ATC H04A?

Featured snippet answer: The expiration dates that matter are those tied to (1) drug product formulation patents and (2) device-delivery patents listed or asserted in litigation, not just earliest composition patents.

How to prioritize expiration dates

Rank patents by:
- Orange Book listing status (for small molecule ANDA relevance)
- litigation assert status (if sued under Paragraph IV)
- claim coverage over the exact dosage form (intranasal vs autoinjector vs prefilled syringe)
- manufacturing and process claims, which can block “same drug, different process” workarounds

Which companies are challenging H04A glucagon patents through Paragraph IV or biosimilar pathways?

Featured snippet answer: Generic and biosimilar challenges in H04A typically target the most formulation- and device-sensitive entries, using Paragraph IV suits for listed patents tied to the NDA drug product and brand-specific presentation.

How challenges show up in the real world

A challenge is most commercially relevant if it targets:
- stability/formulation patents that define the product’s presentation
- delivery device patents that prevent a “bioequivalent” substitute from being commercially deployable

What to track in litigation dockets

Parties: generic sponsor, brand NDA holder, device integration partners
Claims: infringement of formulation or device patents
Remedies: entry date schedules and carve-outs for protected dosage forms

What generic entry risks exist for glucagon rescue products if key formulation or device patents are invalidated?

Featured snippet answer: Even if composition patents fall, device and formulation patents can still prevent market entry. Most launch risk is tied to whether the generic sponsor can commercialize a stable, labeled, and device-compatible product without infringing remaining patents.

Launch scenario map

Only composition patents invalidated
- Residual device/formulation claims often keep entry blocked or force a different presentation.
Formulation patents invalidated or designed around
- Still face device patents and method-of-use label carve-outs.
Device patents invalidated
- Can enable delivery-platform substitutions, but stability requirements remain.
Method-of-use patents remain
- Could limit label to “non-protected” dosing instructions, reducing payer uptake.

What formulations are protected by ATC H04A patent estates (intranasal vs autoinjector vs reconstituted kits)?

Featured snippet answer: Patent protection is often presentation-specific, with different estates for intranasal glucagon devices versus injectable auto-injectors and reconstituted kits.

Formulation and device hotspots

Intranasal delivery

Nose delivery geometry and dose metering patents
Formulation viscosity, particle interaction (if relevant), and stability

Auto-injectors and prefilled injections

Stability in prefilled syringes/cartridges
Needle safety and deployment timing patents
Volume/precision requirements tied to dosing accuracy

Reconstituted emergency kits

Patents can cover:
- lyophilized cake stability and reconstitution time windows
- solvent volume and mixing requirements
- residual powder aggregation controls

How does ATC H04A patent strength compare across glucagon rescue modalities?

Featured snippet answer: Patent strength is typically higher for delivery-integrated modalities (intranasal and auto-injector) because they combine device, formulation, and usability-linked method-of-use claims in layered estates.

Modality comparison matrix (investor and litigant lens)

Injectable prefilled formats: strong formulation + device overlap
Intranasal: strong device metering + formulation stability, plus label navigation risk
Reconstituted kits: can be strong on manufacturing and stability, but sometimes easier to redesign if device is less central

What patent litigation affects ATC H04A exclusivity, and what settlement terms typically drive launch timing?

Featured snippet answer: In glucagon rescue, litigation commonly targets listed drug product and delivery device patents. Settlements frequently define a permitted launch date and may require design-around constraints.

Typical settlement mechanics

entry dates tied to last-expiring asserted patent
dismissal of certain asserted claims contingent on launch timing
covenants not to sue for non-infringing versions
design-around obligations for device geometry and labeling

Docket signals that matter commercially

consolidated cases across multiple generic entrants
repeat filings (continuations) that extend secondary patent layers
settlements that stagger launch dates by patent group

What is the Orange Book status of H04A glucagon therapies?

Featured snippet answer: Orange Book coverage is critical for formulation- and drug product patents listed against the NDA for glucagon rescue products. Where Orange Book listings include multiple patents, the “last listed” expiration drives generic ANDA launch eligibility.

Orange Book analytics to apply

Identify:
- listed patents by number, type (composition, formulation, method of use)
- expiration dates
- patent dispute status via court dockets
Map patents to dosage form:
- intranasal vs injectable product identifiers
- strengths and kit packaging

How do FDA regulatory pathways shape ATC H04A market timing (505(b)(2), ANDA, and biosimilar routes)?

Featured snippet answer: FDA pathway selection governs whether the sponsor must wait out exclusivity, whether it can file via ANDA, and whether biosimilar standards create additional clinical and manufacturing validation gates.

Pathway impact on launch risk

ANDAs for generic small molecules: constrained by Orange Book patents and patent infringement outcomes.
505(b)(2) supplement-driven reformulations: can extend exclusivity indirectly via new dosing forms or labeling.
Biosimilar pathways: for biologic analogs, biologics exclusivity and interchangeability considerations can slow entry even when patents expire.

Key Takeaways

ATC H04A market dynamics are anchored in emergency hypoglycemia rescue, where substitution friction comes from delivery system usability and stability in ready-to-use presentations.
Patent protection is layered: composition plus formulation stability, then device delivery mechanics and method-of-use labeling.
Generic and biosimilar entry timing is most sensitive to the last-expiring listed drug product and delivery-related patents, not the earliest active ingredient filings.
Litigation and settlements often define the real-world launch date by grouping patents into “will/won’t launch” packages.
Orange Book status plus device-specific patent claims are the fastest way to forecast generic entry risk for glucagon rescue products.

FAQs

1) What patent types most often block generic glucagon rescue products?
Drug product formulation patents, device-delivery patents, and method-of-use patents tied to emergency hypoglycemia administration and label.

2) Do intranasal glucagon products face different IP barriers than injectable glucagon?
Yes. Intranasal development typically adds dose metering, applicator geometry, and nasal delivery stability constraints that extend beyond injectable-specific estates.

3) What determines whether a generic can launch “at risk” for H04A drugs?
The status of Orange Book-listed patents tied to the exact dosage form and the outcome of any Paragraph IV litigation or stay/settlement terms.

4) How do device patents affect FDA approval and commercial launch even if formulation is non-infringing?
Device patents can prevent commercially viable product commercialization due to required delivery system design, even if the drug solution itself does not infringe.

5) What common settlement terms show up in glucagon rescue patent disputes?
Launch date covenants, design-around obligations, and dismissal of asserted claims conditioned on entry timing.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
USPTO. Patent Public Search and Patent Center (for assignment, family, and publication data). United States Patent and Trademark Office.

Subclasses in ATC: H04A - GLYCOGENOLYTIC HORMONES